Key facts
- This page summarizes Richard J. Berman's Form 4 filing for BIOVIE INC. (BIVI).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 07 Jan 2025, 17:24.
Richard J. Berman - 20 Nov 2024 Form 4 Insider Report for BIOVIE INC. (BIVI)
- Reporting relationship
- Director
- Issuer ticker
- BIVI
- Reported as of
- 20 Nov 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 07 Jan 2025, 17:24:53 UTC
- Prior SEC filing
- 28 Aug 2024
- Next SEC filing
- 06 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /S/ RICHARD J BERMAN
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Richard J. Berman filed Form 4 for BIOVIE INC. (BIVI) on 07 Jan 2025.
Change
- Previous filing in this sequence was filed on 28 Aug 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BIVI
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +34,200
- Change %
- +531%
- Price
- $0.000000
- Shares after
- 40,643
- Date
- 20 Nov 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BIVI
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +23,155
- Change %
- Price
- $0.000000
- Shares after
- 23,155
- Date
- 20 Dec 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 23,155
- Exercise price
- $1.90
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents a restricted stock unit ("RSU") grant, which was approved by the compensation committee of the issuer's board of directors, subject to board approval, which was obtained on November 20, 2024. Each RSU represents a contingent right to receive one share of the issuer's Class A common stock. The RSUs vest in four equal installments on February 8, 2025, May 8, 2025, August 8, 2025 and the earlier of November 8, 2025 and the date of the issuer's 2025 annual shareholders' meeting.
Footnote F2
The options vest in three equal installments on December 20, 2024, December 20, 2025 and December 20, 2026.